dimiracetam enantiomer (MP-101) / Novaremed - LARVOL DELTA

Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals (Businesswire) - "Novaremed AG...announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its development programs, in an all-share transaction. The acquisition broadens Novaremed’s existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment, the Company’s focus area. Moreover, it enables Novaremed to target a wider spectrum of neuropathic pain indications, potentially also addressing broader applications by including prevention in addition to the treatment of pain...NRD.E1, an orally active small molecule with a novel mechanism of action and patent protection until 2040...MP-101...The Phase 2 trial is expected to start in the first quarter of 2023."

M&A • New P2 trial • Patent • CNS Disorders • Pain • Peripheral Neuropathic Pain